Stamford et al. 5 (n = 105) |
Inclusion on government distribution lists |
Year of publication |
NA |
NA |
NA |
2012 |
Campos Neto et al. 10 |
NA |
Antineoplastic drugs and immune modulators |
NA |
NA |
NA |
2012 |
Campos Neto et al. 10 (n = 2,412) |
Rheumatoid arthritis, type I diabetes mellitus, chronic obstructive pulmonary disease, and ankylosing spondylitis. |
Adalimumab, etanercept, ursodeoxycholic acid, infliximab, and insulin glargine. |
NA |
NA |
NA |
2012 |
Sartoni Junior D et al. 6 (n = 13) |
Rheumatoid arthritis, type I diabetes mellitus, chronic obstructive pulmonary disease, and ankylosing spondylitis. |
Adalimumab, etanercept, ursodeoxycholic acid, infliximab, and insulin glargine. |
NA |
NA |
NA |
2012 |
Diniz et al. 19 |
Fabry’s disease * |
Alpha-galactosidase ** |
Private |
0% |
NA |
2012 |
(n = 196) |
Type IV mucopolysaccharidosis *** |
Galsulphase ** |
NA |
NA |
NA |
2012 |
Machado et al. 8 (n = 827) |
NA |
Adalimumabe, etanercepte, insulina glargina, omeprazol, aripiprazol
|
Privado |
5% |
19,6% presente na RENAME, 11,1% essenciais pela lista da Organização Mundial da Saúde; 24,3% alto custo; 10,9% atenção básica, 3,5% estratégico. 56,7% fora de lista |
2011 |
Sant’ Ana et al. 9 (n = 27) |
NA |
Furosemida; digoxina; clonazepam; ácido acetilsalicílico; enalapril e bromazepam. |
50% privado, 50% público |
0,9% |
45,2% RENAME; 13,9% excepcionais |
2011 |
Borges & Ugá 12 (n = 2062) |
NA |
NA |
NA |
NA |
52% presentes em listas do Ministério da Saúde |
2010 |
Chieffi & Barata 16 (n = 2.927) |
NA |
Insulina glargina e lispro, adalimumabe, etanercepte, infliximabe |
NA |
NA |
NA |
2010 |
Lopes et al 17 (n = 1.220) |
Câncer #
|
Bevacizumabe, capecitabina, cetuximabe, erlotinibe, imatinibe, rituximabe, temozolomida |
Privado |
2006: 14% 2007: 10% ##
|
NA |
2010 |
Stamford et al. 5 (n = 105) |
NA |
Antineoplastic drugs and immune modulators |
NA |
NA |
NA |
2012 |
Campos Neto et al. 7 (n = 2,412) |
Rheumatoid arthritis, type I diabetes mellitus, chronic obstructive pulmonary disease, and ankylosing spondylitis |
Adalimumab, etanercept, ursodeoxycholic acid, infliximab, and insulin glargine |
NA |
NA |
NA |
2012 |
Sartoni Junior et al. 6 (n = 13) |
Fabry’s disease * |
Alpha-galactosidase ** |
Private |
0% |
NA |
2012 |
Diniz et al. 19 (n = 196) |
Type IV mucopoly- saccharidosis *** |
Galsulphase ** |
NA |
NA |
NA |
2012 |
Biehl et al. 2 (n = 1,080) |
Essential hypertension, diabetes mellitus, chronic viral hepatitis, ischemic heart disease, and chronic obstructive pulmonary disease |
Teriparatide, clopidogrel, insulin glargine, rituximab, infliximab |
Public |
NA |
Essential drugs 28%; exceptional drugs 27%; special drugs 11%; one strategic action; 56% not on list |
2012 |
Macedo et al. 13 (n = 81) |
NA |
NA |
NA |
NA |
14.3% primary care and 19.5% exceptional |
2011 |
Machado et al. 8 (n = 827) |
NA |
Adalimumab, etanercept, insulin glargine, omeprazole, aripiprazole
|
Private |
5% |
19.6% on RENAME list; 11.1% WHO essential drugs; 24.3% high-cost; 10.9% primary care, 3.5% strategic. 56.7% not on list |
2011 |
Sant’ Ana et al. 9 (n = 27) |
NA |
Furosemide; digoxin; clonazepam; acetyl-salicylic acid; enalapril and bromazepam |
50% private, 50% public |
0.9% |
45.2% RENAME; 13.9% exceptional |
2011 |
Borges & Ugá 12 (n = 2,062) |
NA |
NA |
NA |
NA |
52% on Ministry of Health lists |
2010 |
Chieffi & Barata 16 (n = 2,927) |
NA |
Insulin glargine and lispro, adalimumab, etanercept, infliximab |
NA |
NA |
NA |
2010 |
Lopes et al 17 (n = 1,220) |
Cancer #
|
Bevacizumab, capecitabine, cetuximab, erlotinibe, imatinibe, rituximab, temozolomide |
Private |
2006: 14% 2007: 10% ##
|
NA |
2010 |
Pepe et al. 10 (n = 185) |
Hypertension, diabetes mellitus, degenerative diseases of the nervous system, chronic lower airway diseases, and end-stage renal disease |
NA |
NA |
NA |
35.8% of drugs on RENAME list and 48.1% on government distribution lists |
2010 |
Pereira et al. 20 (n = 622) |
Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, hepatitis C, ischemic heart disease, hypertension, cancer, and diabetes |
Infliximab, leflunomide, etanercept, adalimumab, propatyl nitrate, clopidogrel, enalapril,carvedilol, simvastatin, insulin glargine |
Private |
1,4% |
Exceptional/high-cost drugs 26.4%; primary pharmaceutical care 2.4%; mental health 1.5%; strategic 1.4%; cystic fibrosis 1% |
2010 |
Chieffi & Barata 14 (n = 2,927) |
NA |
NA |
Public |
3% |
23% supplied by SUS,;13% belonged to Program for Dispensing Exceptional Drugs; |
2009 |
Leite et al. 18 (n = 2,426) |
NA |
NA |
NA |
NA |
32% of requested drugs were part of standard distribution in the SUS |
2009 |
Vieira & Zucchi 15 (n = 170) |
Diabetes mellitus, cancer, comorbidities related to hypertension and diabetes |
NA |
Public |
2 without registration |
62% part of REMUME – São Paulo, or the list of the Program for Dispensing Exceptional Drugs (High-Cost) |
2007 |
Messeder et al. 11 (n = 389) |
Until 1998: HIV. 2000: Crohn’s disease, chronic hepatitis C, and kidney disease 2001 and 2002: essential hypertension and chronic ischemic heart disease |
2000: botulin toxin type A, riluzole and olanzapine. 2001: cyproterone acetate and goserelin acetate. 2002: sevelamer hydrochloride and mesalazine |
Public
|
NA |
31.4 % exceptional, 18.2% strategic, 14/08% primary care, 19% mental health, 3.7% state, 30.8% with no definition of funding
|
2005 |